Form 4: Amgen Director Michael Drake's Stock Grant

Amgen Director Michael V. Drake reported the acquisition of 121.4308 shares of common stock through a restricted stock unit grant, increasing his direct beneficial ownership to 4,699.0291 shares.

Summary

• Michael V. Drake, a Director of Amgen Inc. (AMGN), reported a change in his beneficial ownership.
• On August 8, 2025, Drake acquired 121.4308 shares of Amgen Common Stock.
• These shares were granted as Restricted Stock Units (RSUs) under the Amgen Inc. 2009 Director Incentive Program and vested immediately.
• The grant price was $0 per share, indicating it was compensation.
• Following this transaction, Drake directly beneficially owns 4,699.0291 shares of Amgen Common Stock.
• The total shares include 227 Dividend Equivalents (DEs) credited on vested but deferred RSUs, paid out in shares on a one-to-one basis along with a cash payment for any remaining fractional share amount.

Sentiment

Score: 7

Explanation: The filing indicates a routine equity grant to a director, which is a positive sign of aligning management interests with shareholders, without any negative implications such as sales or unusual transactions.

Positives

• Director Michael V. Drake increased his direct beneficial ownership in Amgen Inc.
• The acquisition of shares through Restricted Stock Units (RSUs) aligns the director's interests with those of shareholders.

Negatives

• None directly apparent from this Form 4 filing.

Risks

• NA

Future Outlook

NA

Management Comments

• NA

Industry Context

This filing reflects routine compensation practices for directors in publicly traded companies, where equity grants like Restricted Stock Units (RSUs) are common to align executive and director interests with shareholder value.

Comparison to Industry Standards

• The grant of Restricted Stock Units (RSUs) at a $0 price is a standard compensation practice for directors in the pharmaceutical and biotechnology industry, similar to practices at companies like Pfizer (PFE) or Johnson & Johnson (JNJ), where equity-based compensation is used to incentivize long-term performance and retention.
• The immediate vesting of RSUs for directors is also a common practice, differing from employee grants which often have multi-year vesting schedules.

Management Changes

Corporate Governance

Legal Proceedings

• NA

Related Party Transactions

• The acquisition of shares by Director Michael V. Drake through Restricted Stock Units (RSUs) is a related party transaction, representing a component of his compensation under the Amgen Inc. 2009 Director Incentive Program.

Stakeholder Impact

• Shareholders: Interests are further aligned with the director through increased equity ownership.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned.

Next Steps

• NA

Key Dates

Recommendation

This Form 4 reports a routine equity grant to a director as part of their compensation, which is a standard practice to align interests. It does not provide new information that would fundamentally alter the investment thesis for Amgen Inc., thus a 'hold' recommendation remains appropriate based solely on this filing.

Keywords

Amgen, AMGN, Director, Insider Transaction, Stock Grant, Restricted Stock Units, RSU, Beneficial Ownership, SEC Form 4